Immunotherapeutic Approach For Treating Metastatic Tumors Reported In Science

October 02, 1997

-- Heat Shock Proteins Demonstrate Potential As Patient-Specific Treatments --

New York, NY, October 2, 1997 - Researchers at the Center for Immunotherapy of Cancer and Infectious Diseases at the University of Connecticut School of Medicine announced today the publication of a scientific report in the current issue of Science (vol. 278, n. 5335) that describes a powerful new approach to using immunotherapy for the treatment of a variety of cancers, including metastatic disease. With this approach, the individual's own immune cells are stimulated to eliminate cancerous cells from the body.

The paper, entitled "Immunotherapy of Tumors with Autologous Cancer-Derived Heat Shock Protein Preparations," describes the use of protein complexes purified from tumor cells in the treatment of cancer and metastasis. Heat shock proteins (HSPs) are a family of molecular chaperones present in all cells. In this study, 80% of HSP-treated mice survived for longer than 250 days compared to fewer than 20% of control mice.

The approach to immunotherapy of cancer described in the report is medically significant because it is applicable to virtually all forms of cancer. Heat shock proteins can be purified from a tumor specimen removed by surgery or biopsy. The paper describes the treatment of five different kinds of cancers in mice, including metastatic lung cancer, melanoma and colon carcinoma.

The versatility of heat shock proteins in the treatment of cancer derives from their normal physiological role in cells. HSPs play a role in protein trafficking, whereby they keep other proteins in their correct shape and location. When these molecular chaperones are purified from cells, they bring along with them small fragments, or peptides, derived from other proteins expressed in that cell, providing a molecular "fingerprint" of the cell's content. Vaccination with the HSP-peptide complexes purified from cancer cells has the potential to specifically stimulate the immune system to attack cells bearing those peptides, i.e., the cancer cells themselves.

"The HSP-peptide complex vaccination is perhaps the first general principle of immunization which now has shown to be effective against a wide variety of pre-existing cancers," said Pramod K. Srivastava, Ph.D., of the University of Connecticut School of Medicine and Principle Investigator for the project. "Decades of research suggests that tumors are distinct from one individual to another, with each tumor containing its own unique set of mutations. The task of identifying each of these mutations in individual cancer patients -- with the intent of targeting them immunotherapeutically -- is therefore impractical. In contrast, the process of purifying HSPs is the same for each patient's tumor and is relatively simple."

This immunotherapeutic approach can target the cancer-specific antigens of any cancer cell without the need to identify what those antigens are. Moreover, the results from this paper demonstrate that the vaccine is effective against the primary tumor and its metastases. In human clinical settings, metastatic cancer is frequently untreatable and fatal even if the primary cancer has been removed successfully.

Antigenics, L.L.C., holds the commercial rights to the HSP-based vaccines against cancer and infectious diseases. "We have initiated a Phase I trial in pancreatic cancer where HSP-based vaccines are being prepared from individual cancer patients' tumors. Phase Ib clinical trials for the treatment of melanoma and renal cell carcinoma are expected to start in the fourth quarter 1997," said Garo Armen, Ph.D., Chief Executive Officer of Antigenics.

"We anticipate that vaccinating cancer patients with purified chaperone-peptide complexes will lead to a decrease in the size of the tumor and will treat metastasis. This approach, alone or in combination with surgery and chemotherapeutic treatments should extend and improve the quality of life for patients with a wide variety of cancers." Further, Armen said, "heat shock protein technology provides Antigenics with a platform that also has applications for the treatment of many infectious diseases.

The Center for Immunotherapy of Cancer and Infectious Diseases within the University of Connecticut School of Medicine at Farmington, CT is involved in basic and clinical research on immune responses to cancer and infectious diseases, and on problems in autoimmunity.

Antigenics, L.L.C., is a privately-held biopharmaceutical company developing treatments for cancer, infectious diseases and other disorders. These treatments are based on the Company's proprietary technology which utilizes the ability of heat shock proteins, the body's natural adjuvants, to modulate the immune system selectively.

Editor's notes: Dr. Pramod Srivastava will be available for interviews while currently in India, through the contacts listed above.

This release is also available on the Internet at: and at after 4:00pm on Thursday, October 2.

Noonan/Russo Communications

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to